ArticleJournal of hepatocellular carcinoma2026
Multicenter Validation of a RAR-Based Nomogram for Predicting Postoperative Progression in HBV-Related Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The red cell distribution width-to-albumin ratio (RAR) is a biomarker reflecting systemic inflammation and oxidative stress, and has been associated with outcomes in multiple diseases. However, its value for predicting postoperative recurrence or progression in hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) remains undetermined. Methods: We retrospectively reviewed 1 011 HBV-HCC patients who underwent surgical treatment at three tertiary centres. Patients were divided into training, internal validation and external validation cohorts. The performance of RAR for predicting progression-free survival (PFS) was assessed using receiver operating characteristic (ROC) analysis, and restricted cubic spline (RCS) modelling was used to explore its nonlinear association with progression risk. Independent prognostic factors were identified by multivariate Cox regression and incorporated into a nomogram and an interactive web-based calculator, which were validated in all cohorts. Results: RAR achieved an area under the ROC curve (AUC) of 0.662 for predicting PFS. RCS analysis revealed a nonlinear increase in progression risk with rising RAR values, with the curve plateauing at higher levels. Multivariate Cox analysis confirmed RAR as an independent predictor of postoperative PFS (hazard ratio [HR] = 4.40; 95% CI, 1.74-11.12). The nomogram-integrating RAR, tumour size, alpha-fetoprotein, TNM stage and portal vein tumour thrombus (PVTT)-demonstrated Satisfactory discrimination, excellent calibration and consistent net clinical benefit across data sets. Conclusion: RAR independently predicts postoperative recurrence or progression in HBV-HCC. The RAR-based nomogram offers a practical tool for individualised estimation of PFS, facilitating more precise postoperative risk stratification and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.